Hypermethylation biomarkers associated with poor survival outcomes for head and neck squamous cell cancer

Patent metadata

Field	Value
Publication number	US-10457992-B2
Application number	US-201415032638-A
Country	US
Kind code	B2
Filing date	Oct 29, 2014
Priority date	Oct 30, 2013
Publication date	Oct 29, 2019
Grant date	Oct 29, 2019

Abstract

In accordance with one or more embodiments, the inventors have conducted the first comprehensive integrated genomic and epigenomic analysis in HNSCC, focusing on identifying genes that have concurrent promoter methylation, mutation and expression downregulation. The intersection of unbiased genome-wide methylation sequencing and methylation array screens uncovered 316 genes, which undergo promoter methylation in HNSCC. Close to 60% concordance was found between concurrent greater promoter methylation and gene downregulation, with PAX1 and PAX5 exhibiting the greatest expression loss. Methods for analyzing tissue samples from a subject for increased risk of poor survival outcomes from HNSCC are provided. Kits for measuring promoter methylation of the genes are also provided.

First claim

The invention claimed is:

1. A method for identifying an increased risk for a poor survival outcome in a subject having head and neck squamous cell cancer comprising:
a) obtaining nucleic acid from a test sample from the subject, wherein the test sample is from a specimen selected from the group consisting of a tissue specimen, a biopsy specimen, a surgical specimen, saliva, and a cytological specimen;
b) performing bisulfite modification to the nucleic acid in a);
c) performing quantitative methylation specific PCR (QMSP) on bisulfite modified nucleic acid from b) using PCR primers and probes specific for the promoter region of one or more genes of interest, wherein the one or more genes of interest are selected from the group consisting of PAX1, PAX5, ZIC4, and PLCB1, and the primers and probes are selected from the group consisting of SEQ ID NOS: 4-15;
d) determining the promoter methylation level of the promoter regions of the one or more genes of interest in the nucleic acid from the test sample of the subject;
e) providing a reference non-neoplastic sample, wherein the reference non-neoplastic sample is from a specimen selected from the group consisting of a tissue specimen, a biopsy specimen, a surgical specimen, saliva, and a cytological specimen;
f) comparing the level of promoter methylation of the one or more genes of interest from the test sample of the subject, to the level of promoter methylation of the one or more genes of interest in a reference non-neoplastic sample;
g) identifying an increased risk of poor survival outcome for the subject having head and neck squamous cell cancer when the level of promoter methylation of the one or more genes of interest in the test sample of the subject, is increased relative to the level of promoter methylation of the one or more genes of interest in the reference non-neoplastic test indicating epigenetic silencing of the one or more genes of interest; and
h) adjusting or modifying the planned treatment of the subject as a result of the increased risk of poor survival in the subject having head and neck squamous cell cancer.

2. The method of claim 1 wherein the test sample contains oral squamous cells or nucleic acids from oral squamous cells.

3. The method of claim 2 , wherein the methylation of at least two genes is detected.

4. The method of claim 2 , wherein the methylation of at least three genes is detected.

5. The method of claim 2 , wherein the methylation of all four genes is detected.

6. The method of claim 1 , wherein the methylation of at least PAX5 is determined.

Assignees

• Univ Johns Hopkins

Inventors

• Guerrero-Preston Rafael
• Michailidi Christina
• Sidransky David

Classifications

• C12Q2600/16

  Primer sets for multiplex assays · CPC title

• C12Q2600/154

  Methylation markers · CPC title

• C12Q2600/158

  Expression markers · CPC title

• C12Q2600/106

  Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism · CPC title

• C12Q1/6886 Primary

  for cancer (immunoassay for cancer G01N33/575) · CPC title